Background
==========

Breast cancer is one of the most common cancers in women, accounting for more than 1,300,000 cases and 450,000 deaths worldwide each year \[[@B1]\]. Breast cancer is a heterogeneous disease that comes in different morphological and immunohistochemical characteristics with corresponding clinical behaviour \[[@B2]\]. The oncogenesis and progression of breast cancer is a complex process involving a variety of transcription factors, activation of oncogenes, and inactivation of tumour suppressor genes \[[@B3],[@B4]\].

Recently gene expression profiling and immunohistochemistry (IHC) studies have been identified Tricho-rhino-phalangeal syndrome-1 gene (*TRPS1*), a new GATA family member, to be highly prevalent gene in breast cancer \[[@B5],[@B6]\]. TRPS is an autosomal dominant genetic disorder characterised by craniofacial and skeletal anomalies due to mutations or deletions of the *TRPS1* gene. It is composed of nine zinc finger motifs including a single GATA-type DNA-binding domain flanked by two potential nuclear localisation signals (NLS) and two C-terminal zinc fingers closely related to the domain found in the Ikaros family of lymphoid transcription factors \[[@B7]\]. It has been demonstrated that *TRPS1* is a transcriptional repressor and its activities are dependent on both the highly conserved GATA DNA-binding domain and the Ikaros-like zinc finger motifs \[[@B8]\]. For example, *TRPS1* can repress Stat3 to regulate proliferation and apoptosis of chondrocytes. *TRPS1* controls epithelial proliferation through repressing SOX9 in the developing vibrissa follicle in mice. It can also repress the expression of Runx2, a key regulator of osteoblastogenesis and chondrocyte maturation \[[@B9]\]. Moreover, *TRPS1* can suppress the osteocalcin expression through binding to its promoter \[[@B10]\].

As mentioned before, TRPS1 gene in human has been found to be overexpressed in breast cancer, expressed in more than 90% estrogen receptor α (ERα) positive and negative breast cancer subtype \[[@B6]\]. The gene is localised on human chromosome 8q23--24.1, a region highly amplified in several cancers, especially in prostate and breast cancer. It is important to note that *TRPS1* gene has been found to be highly expressed not only in the mammary glands but also in prostate, testis, ovaries, kidneys, and lungs \[[@B11]\]. Increasingly, there are more evidences to suggest the involvement of TRPS1 in a variety of functions in human cancers \[[@B12]-[@B15]\].

Recent studies have reported that *TRPS1* can regulate mesenchymal-to-epithelial transition (MET) during embryonic development in a number of tissues, including kidneys, cartilages, and bones \[[@B10],[@B16],[@B17]\]. Epithelial-to-mesenchymal transition (EMT) was first recognised as an important process during normal embryonic development \[[@B18]\]; however, carcinoma cells are also capable of reactivating EMT during tumour progression \[[@B19],[@B20]\]. During this transition, tumour cells lose epithelial characteristics such as cell apical-basal polarity, membrane-associated adherents, and cell-to-cell adhesion protein E-cadherin. Concurrently, these tumour cells also undergo a dramatic remodelling of the cytoskeleton to facilitate cell mortality and invasion; the cells are also transformed to obtain a spindle-like phenotype. A key feature of EMT is a gene switch, resulting in downregulation of E-cadherin and upregulation of vimentin, smooth muscle actin. Transcriptional factors, such as snail, slug, and twist, which function by suppressing the expression of epithelial specific adhesion molecules, such as E-cadherin, were unveiled as key regulators inducing EMT in breast cancer and other cancers \[[@B21]-[@B24]\]. β-catenin was first identified as a protein that binds with E-cadherin to maintain cell-to-cell adhesion; however, it also functions as a transcription factor. Loss of membranous β-catenin expression and gain of cytoplasmic or nuclear β-catenin expression in neoplastic glands have been related to carcinogenesis and tumour progression in gastrointestinal cancers \[[@B25],[@B26]\]. Thus, by detecting these EMT markers, one can roughly estimate the tumour cells undergoing EMT from non-EMT tumour cells.

In addition to the involvement of *TRPS1* in regulating MET, it has also been found to repress ZEB2, a key regulator of EMT that inhibits E-cadherin and other epithelial genes \[[@B12]\]. Realizing the potential of TRPS1 gene as the new EMT marker, we focused our work in elucidating different roles and clinical relevance of *TRPS1* in ERα-positive and ERα-negative breast cancer subtypes.

Methods
=======

Patients and tissue samples
---------------------------

This study was conducted on 180 paraffin-embedded breast samples, which were histopathologically diagnosed invasive ductal carcinoma during 2007 to 2009 at the Department of Pathology of Qilu Hospital of Shandong University. For using these clinical materials for research purposes, prior patient consent and approvals from the Research Ethics Committee of Shandong Medical University were obtained. All the diagnoses were made following the Pathology and Genetics of Tumours of the Breast and Female Genital Organs of World Health Organisation Classification of Tumours.

Tissue microarray
-----------------

For each hematoxylin and eosin (H&E)-stained slide, two representative areas were selected and the corresponding spots were marked on the surface of the paraffin block. Using a tissue microarray (TMA) punching instrument, the selected areas were punched out and were placed into the recipient block side by side. Each tissue core was 2 mm in diameter and was assigned with a unique TMA location number that was linked to a database containing other clinicopathologic data \[[@B27]\].

Immunohistochemistry
--------------------

The immunohistochemical study was carried out to examine altered protein expression in 180 paraffin-embedded breast tissues as described in previous publications \[[@B28]\]. All the markers were incubated with the sections overnight at 4°C; the markers included *TRPS1* (sc-26974, diluted 1:200; Santa Cruz Biotechnology, CA, USA), P53 (Zhongshan Golden Bridge Biotechnology, ZSGB-Bio, Beijing, China), E-Cadherin (24E10, diluted 1:400, Cell Signalling Technology, USA), mouse monoclonal antibody β-catenin (E-5, diluted 1:500, Santa Cruz Biotechnology, CA, USA), Vimentin ( D21H3, diluted 1:100, Cell Signalling Technology, USA), slug (C19G7, diluted 1:50, Cell Signalling Technology, USA); the second antibody was from IHC reagent kit (Zhongshan Biotechnology Company, Beijing, China). After diaminobenzidine (DAB) staining, the sections were counterstained with hematoxylin. For negative controls, the antibodies were replaced with phosphate buffered saline (PBS).

Evaluation of immunohistochemical staining
------------------------------------------

The stained slides were reviewed and evaluated independently by two observers blinded to patients' information. A dual semi-quantitative scale, combining the staining intensity as well as percentage of positive cells, was used to evaluate the protein staining. In brief, staining of *TRPS1* was scored semi-quantitatively for intensity (0 = no expression, 1 = weak, 2 = moderate, and 3 = strong) and percentage of positive cells (0 = 0--10%, 1 = 10--30%, 2 = 30--50%; 3 = 50--80%, and 4 = 80--100%). The final score of TRPS1 was the staining score multiplied by the percentage of positive cells. The following cut-off levels were applied: 0 for negative and ≥ 1 for positive \[[@B15]\]. For β-catenin, membrane and cytoplasmic/nuclear expression were recorded separately as no staining, weak staining, or strong staining. Cases with more than 50% of nuclei stain were considered nuclear staining while cases with more than 50% of cytoplasm stain were considered cytoplasmic staining \[[@B29]\]. ER or PgR was positive if 1% of tumour cell nuclei were immuno reactive \[[@B30]\]. For other molecular markers, tumours were regarded as immune-positive if \> 10% of tumour cells showed immunoreactivity. Cytoplasmic staining was considered positive for vimentin and SMA. Nuclear staining was considered positive for *TRPS1*, ERβ, slug and P53. Membranous staining was considered positive for E-cadherin.

Statistical analysis
--------------------

Statistical analyses were performed using the statistics software package SPSS 18.0 (SPSS, Chicago, IL). Chi-square test or Fisher's exact test were performed to evaluate the correlation between *TRPS1* expression and clinicopathologic characteristics, if appropriate. Bivariate correlations between study variables were calculated by Spearman's rank correlation coefficients. Differences were considered statistically significant for P values \< 0.05.

Results
=======

Relationship of *TRPS1* over-expression with the clinical features in breast cancer
-----------------------------------------------------------------------------------

In the analysis of a 180-member TMA, we found positive TRPS1 expression in 93 cases (51.7%), while 87 tumours (48.3%) were negative. Table [1](#T1){ref-type="table"} shows no significant correlation between the expression level of *TRPS1* and biological factors such as histology grade (P = 0.903), pathological stage (P = 0.646), tumour size (P = 0.343), lymph node metastasis (P = 0.443), P53 status (P = 0.113), and IMP3 status (P = 0.618). In contrast, we found that *TRPS1* expression was strongly correlated with the patients' age (P = 0.017), Ki67 (P = 0.002), ERα (P \< 0.001), progesterone receptor (PR) (P \< 0.001), HER2 (P = 0.025), and ERβ status (P = 0.001). Spearman correlation analysis was preformed to confirm further the correlation between *TRPS1* expression and patients' age (−0.179, P = 0.016); Ki67 (−0.233, P = 0.002), ERα (0.333, P \< 0.001), PR (0.31, P \< 0.001), HER2 (−0.166, P = 0.025), and ERβ status (0.242, P = 0.001). We divided the patients into two groups as ERα-positive and ERα-negative. *TRPS1* expression was observed in 69 (65.7%) of 105 ERα-positive patients, while in 24 (32%) of 75 ERα-negative patients.

###### 

Correlation between TRPS1 expression and the clinicopathologic characteristics of breast cancer patients

    **Characteristics**    **n**   **TRPS1 expression**   ***P*value**   **Spearman**   **Value (r)**   ***P*value**  
  ----------------------- ------- ---------------------- -------------- -------------- --------------- -------------- ---------
          Age(y)                                                                                                           
            ≤50             70              26                 44           0.017                          −0.179       0.016
           \>50             110             61                 49                                                          
           Grade                                                                                                           
             I              11              5                  6            0.903                                          
            II              124             59                 65                                                          
            III             45              23                 22                                                          
    Pathological stage                                                                                                     
             I              49              23                 26           0.646                                          
            II              85              44                 41                                                          
            III             46              20                 26                                                          
        Tumor size                                                                                                         
            \<2             60              26                 34           0.343                                          
            ≥2              120             61                 59                                                          
   Lymph node metastasis                                                                                                   
         Negative           94              48                 46           0.443                                          
         Positive           86              39                 47                                                          
    Expression of Ki67                                                                                                     
           ≤25%             62              20                 42           0.002                          −0.233       0.002
           \>25%            118             67                 51                                                          
     Expression of P53                                                                                                     
         Negative           72              40                 32           0.113                                          
         Positive           108             47                 61                                                          
            ERα                                                                                                            
         Negative           75              51                 24          \<0.001                         0.333       \<0.001
         Positive           105             36                 69                                                          
            PR                                                                                                             
         Negative           75              50                 25          \<0.001                          0.31       \<0.001
         Positive           105             37                 68                                                          
           HER-2                                                                                                           
         Negative           124             53                 71           0.025                          −0.166       0.025
         Positive           56              34                 22                                                          
        E-cadherin                                                                                                         
         Negative           33              24                 9            0.002                          0.231        0.002
         Positive           147             63                 84                                                          
           Slug                                                                                                            
         Negative           170             86                 84           0.019                          0.186        0.012
         Positive           10              1                  9                                                           
         Vimentin                                                                                                          
         Negative           165             84                 81           0.022                          0.171        0.022
         Positive           15              3                  12                                                          
            SMA                                                                                                            
         Negative           169             85                 84           0.039                          0.154        0.039
         Positive           11              2                  9                                                           
         β-catenin                                                                                                         
         Negative           67              42                 25           0.003                          0.221        0.003
         Positive           113             45                 68                                                          
            ERβ                                                                                                            
            ≤2              92              55                 37           0.001                          0.242        0.001
            \>2             87              31                 56                                                          
           IMP3                                                                                                            
         Negative           157             77                 80           0.618                                          
         Positive           23              10                 13                                                          

Relationship of *TRPS1* expression with EMT markers in breast cancer
--------------------------------------------------------------------

As *TRPS1* may be a critical regulator of EMT during breast cancer initiation and progression, the expression of EMT markers, including E-cadherin, β-catenin, vimentin, SMA and slug, were stained in human breast cancer TMA. Statistical analysis indicated that the immunohistochemical expression of *TRPS1* is directly correlated with E-cadherin (P = 0.002) and β-catenin (P = 0.003), which was further confirmed by Spearman correlation analysis (E-cadherin: r = 0.231, P = 0.002; β-catenin: r = 0.221, P = 0.003) (Table [1](#T1){ref-type="table"}). Moreover, we also found that *TRPS1* expression was significantly correlated with slug (P = 0.019), vimentin (P = 0.022) and SMA (P = 0.039); the corresponding Spearman correlation values are 0.186 (P = 0.012), 0.171 (P = 0.022), and 0.154 (P = 0.039).

Correlation between *TRPS1* expression and molecular markers in ERα-positive breast cancer
------------------------------------------------------------------------------------------

We analysed the molecular markers in ERα-positive breast cancer. Table [2](#T2){ref-type="table"} shows the expression of *TRPS1* is positively associated with E-cadherin (P \< 0.001), β-catenin (P = 0.001), ERβ (P = 0.03), and p53 (P = 0.002) status (Figure [1](#F1){ref-type="fig"}). However, the *TRPS1* expression is not associated with slug (P = 0.549), vimentin (P = 0.296), SMA (P = 0.296), and IMP3 (P = 0.605).

###### 

**Correlation between TRPS1 expression and molecular markers in ER**α **positive breast cancer patients**

   **Characteristics**         **n**         **TRPS1 expression**   ***P*value**   **Spearman**   **Value (r)**   ***P*value**  
  --------------------- ------------------- ---------------------- -------------- -------------- --------------- -------------- ---------
         Age(y)                                                                                                                      
           ≤50                  42                    9                  33           0.023                          −0.221       0.023
          \>50                  63                    27                 36                                                          
                         Expression of P53                                                                                           
        Negative                45                    23                 22           0.002                          0.307        0.001
        Positive                60                    13                 47                                                          
                            E-cadherin                                                                                               
        Negative                16                    13                 3           \<0.001                          0.42       \<0.001
        Positive                89                    23                 66                                                          
          Slug                                                                                                                       
        Negative                102                   36                 66           0.549                                          
        Positive                 3                    0                  3                                                           
        Vimentin                                                                                                                     
        Negative                101                   36                 65           0.296                                          
        Positive                 4                    0                  4                                                           
           SMA                                                                                                                       
        Negative                101                   36                 65           0.296                                          
        Positive                 4                    0                  4                                                           
        β-catenin                                                                                                                    
        Negative                34                    19                 15           0.001                          0.315        0.001
        Positive                71                    17                 54                                                          
           ERβ                                                                                                                       
           ≤2                   46                    21                 25            0.03                          0.211        0.03
           \>2                  59                    15                 44                                                          
          IMP3                                                                                                                       
        Negative                101                   34                 67           0.605                                          
        Positive                 4                    2                  2                                                           

![**Expression of markers in ERα-positive breast cancer (Magnification 200X). A**. Positive nuclear staining for *TRPS1*, **B**. Positive membranous staining for E-cadherin, **C**. Positive membranous staining for β-catenin, **D**. Positive nuclear staining for ERβ, and **E**. Positive nuclear staining for P53.](1746-1596-9-119-1){#F1}

Correlation between *TRPS1* expression and molecular markers in ERα-negative breast cancer
------------------------------------------------------------------------------------------

For ERα negative breast cancer cases, Table [3](#T3){ref-type="table"} shows that the immunohistochemical expression of *TRPS1* has correlation with slug (P = 0.004), vimentin (P = 0.003), SMA (P = 0.031), and IMP3 (P = 0.005), which was further confirmed by Spearman correlation analysis (Figure [2](#F2){ref-type="fig"}).

###### 

**Correlation between TRPS1 expression and molecular markers in ER**α **negative breast cancer patients**

   **Characteristics**         **n**         **TRPS1 expression**   ***P*value**   **Spearman**   **Value (r)**   ***P*value**  
  --------------------- ------------------- ---------------------- -------------- -------------- --------------- -------------- -------
         Age(y)                                                                                                                     
           ≤50                  28                    17                 11           0.296                                         
          \>50                  47                    34                 13                                                         
                         Expression of P53                                                                                          
        Negative                27                    17                 10           0.483                                         
        Positive                48                    34                 14                                                         
                            E-cadherin                                                                                              
        Negative                17                    11                 6            0.741                                         
        Positive                58                    40                 18                                                         
          Slug                                                                                                                      
        Negative                68                    50                 18           0.004                          0.369       0.001
        Positive                 7                    1                  6                                                          
        Vimentin                                                                                                                    
        Negative                64                    48                 16           0.003                          0.362       0.001
        Positive                11                    3                  8                                                          
           SMA                                                                                                                      
        Negative                68                    49                 19           0.031                          0.271       0.019
        Positive                 7                    2                  5                                                          
        β-catenin                                                                                                                   
        Negative                33                    23                 10            0.78                                         
        Positive                42                    28                 14                                                         
           ERβ                                                                                                                      
           ≤2                   46                    34                 12           0.167                                         
           \>2                  29                    17                 12                                                         
          IMP3                                                                                                                      
        Negative                56                    43                 13           0.005                          0.323       0.005
        Positive                19                    8                  11                                                         

![**Expression of markers in ERα-negative breast cancer (Magnification 200X). A**. Positive nuclear staining for *TRPS1*, **B**. Positive cytoplasmic staining for vimentin, **C**. Positive nuclear staining for slug. **D**. Positive cytoplasmic staining for SMA, and **E**. Positive cytoplasmic staining for IMP3.](1746-1596-9-119-2){#F2}

Discussion
==========

Breast cancer is a heterogeneous disease consisting of multiple molecular subtypes. The presence of hormone receptors ER, PR, and human EGFR-2 (HER-2) are significantly meaningful in therapeutic decision-making for patients with breast cancer. In addition, these factors may also predict the probability of disease relapse. Hormone receptor-positive tumours have favourable outcomes because of their response to endocrine manipulations such as tamoxifen, aromatase inhibitors, or ovarian ablation \[[@B31]\]. Tumours with ERα-negative phenotype tend to have poor prognosis, unlike their hormone receptor or HER-2 positive counterparts; hence, such ERα-negative tumours lack targeted therapeutics.

Next, we investigated the expression of *TRPS1* in primary human breast cancer samples and explored its association with major breast tumour histological specialties and patients' clinical characteristics. *TRPS1* was positively associated with ER and PR expressions and negatively associated with HER2 status, which is consistent with previous study \[[@B6]\].

When the cut-off level score for TRPS1 to be positive is 1, the TRPS1 was not remarkably associated with the tumour grade, pathological stage, tumour size and lymph node metastasis. However, upon changing the cut-off level score of *TRPS1* to be positive as ≥ 2, *TRPS1* was found to be positively associated with lymph node metastasis and P53 status (data not shown).

However, previous studies showed that higher *TRPS1* expression, when analysed using univariate and multivariate models, predicted better overall survival (OS) and disease-free survival (DFS) in a subgroup of ERα+, stage I/II breast cancer patients who received endocrine therapy only \[[@B32]\]. Recent studies have also confirmed that high *TRPS1* expression was significantly associated with lymph node metastasis and higher pathological stage of patients with colon cancer \[[@B14]\]. All these findings support our hypothesis that *TRPS1* may not merely be an indicator of better prognosis as shown in other studies. However, further research using larger patient cohort and more breast cancer cell lines is required to elucidate this contradictory result.

Epithelial cancer cells attain mesenchymal features that make them easier to invade the surrounding tissues and metastasise during EMT process. We used IHC to analyse these markers in 180 patients. Although *TRPS1* was significantly associated with E-cadherin and β-catenin, it was also positively associated with mesenchymal markers such as vimentin, SMA, and slug. The above data did not comply with previous results that *TRPS1* inhibits EMT process in breast cancer progression \[[@B12]\]. Hence, we divided the patients into two groups as ERα-positive and ERα-negative and reanalysed these EMT markers. Surprisingly, in ERα-positive breast cancer, we found *TRPS1* to be positively associated with E-cadherin and β-catenin status with no significant correlation with any of the mesenchymal markers. Consistent with our hypothesis, significant association was also found between *TRPS1* expression and E-cadherin expression in ERα + breast cancer cases \[[@B32]\]. In ERα-negative breast cancer, we found *TRPS1* to be positively associated with vimentin, SMA and slug. *TRPS1* was also found to be positively related with IMP3, which is expressed preferentially in triple negative breast cancers (TNBC). IMP3 is a member of insulin-like growth factor II (IGF-II) mRNA-binding proteins family. It contributes to the migration and invasion of TNBC cells. Thus, *TRPS1* may be associated with the migration, invasion, and EMT in ERα-negative breast cancer cells. Ligand-activated ERα could suppress slug transcription through direct association with the slug promoter. Human breast cancers, which lack ligand-activated ERα, may then over-express slug that may downregulate E-cadherin and lead to EMT \[[@B33]\]. We found *TRPS1* to be associated with different EMT markers by different ERα status, therefore, ERα might play an important role in affecting the relationship between *TRPS1* and EMT markers.

Estrogen receptors include estrogen receptor α (ERα) and estrogen receptor β (ERβ). Most studies have provided evidence that ERβ acts as a negative modulator of ERα and indicates a good prognosis with prolonged DFS \[[@B34],[@B35]\]. Several investigators have found ERβ expression to be positively correlated with poor prognostic phenotypes such as accelerated proliferation and basal phenotype in ERα-negative breast cancer \[[@B36],[@B37]\]. We also stained ERβ and found its expression to be correlated with *TRPS1* expression. *TRPS1* expression was not regulated by ER signalling since estrogen withdrawal using charcoal-stripped serum did not affect *TRPS1* gene or protein expression in ERα-positive breast cancer cell lines \[[@B32]\]. Thus, we have assumed that *TRPS1* might transcriptionally both regulate genes and affect tumour growth and development to varying degrees.

Conclusions
===========

There are many possible explanations for the different association between the molecular markers with *TRPS1* in ERα-positive and ERα-negative breast cancer. First, *TRPS1* is capable of binding to numerous cofactors of various functions. Second, it may either promote or inhibit carcinoma processing depending on the context and amount of protein present \[[@B38],[@B39]\]. Based on the above results, we conclude that *TRPS1* is positively associated with E-cadherin and β-catenin status in ERα-positive breast cancer, while it also has a significant association with mesenchymal markers of EMT in ERα-negative breast cancer. However, further studies with large number of tumours and breast cancer cell lines are required to validate the precise function of *TRPS1* gene in breast cancer.
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